Atherosclerosis and Hyperlipidemia

AHA 22: RESPECT EPA: Eicosapentaenoic Acid for Prevention of Coronary Artery Disease

Hiroyuki Daida, Saahil A Jumkhawala,

Watch time: 14m 14s
Radcliffe & CardioNerds @AHA22: Reduction of Lp(a) With Small Interfering RNA

Gurleen Kaur, Michelle O'Donoghue,

Watch time: 14m 29s
Radcliffe & CardioNerds @AHA22: Reduction of Triglycerides With Pemafibrate

Aruna D Pradhan, Gurleen Kaur,

Watch time: 14m 25s
EP 78: Your Guide to Lipoprotein(a) with Dr. Salim S Virani

Salim S Virani, Ankur Kalra,

Listen time: 46:28
FOURIER-OLE: Implications for Real-World Practice

Robert P Giugliano,

Watch time: 2m 56s
FOURIER-OLE: The Trial in Context

Marc S Sabatine,

Watch time: 3m 24s
FOURIER-OLE: Long-term Safety of Evolocumab Therapy in Patients with Evident ASCVD

Michelle O'Donoghue,

Watch time: 3m 30s

Yassir Javaid, , , et al

Watch time: 1h 6m (4 videos)
4 Lipid Late-breaker Highlights from ACC.22 with Dr Erin Michos

Erin D Michos,

Secondary Analysis of CANTOS Finds LDL & HDL Predict Residual Risk of Atherosclerotic Events

Paul M Ridker,

ACC 22: PACMAN-AMI Shows Reduced Plaque Regression in AMI Patients Treated with Alirocumab

Lorenz Räber,

ACC 22: Magnitude & Duration of Effects of a siRNA Targeting Lp(a)

Steven E Nissen,

Heather Currie , Christine Williams ,

Edward T Carreras , Donna M Polk ,

FOURIER-OLE: Implications for Real-World Practice

Robert P Giugliano,

Watch time: 2m 56s
FOURIER-OLE: Long-term Safety of Evolocumab Therapy in Patients with Evident ASCVD

Michelle O'Donoghue,

Watch time: 3m 30s

Sergio Fazio ,

Marc Sirol ,

Donald E Cutlip ,

Yassir Javaid, , , et al

Watch time: 1h 6m (4 videos)

Jiaqian Xu , Michael D Shapiro ,

Marc P Allard-Ratick , Pratik Sandesara , Arshed A Quyyumi , et al

Kilmer S McCully ,

Leo Buckley , Ahmed Aldemerdash ,

Media

AHA 22: RESPECT EPA: Eicosapentaenoic Acid for Prevention of Coronary Artery Disease

Hiroyuki Daida, Saahil A Jumkhawala,

Watch time: 14m 14s
Radcliffe & CardioNerds @AHA22: Reduction of Lp(a) With Small Interfering RNA

Gurleen Kaur, Michelle O'Donoghue,

Watch time: 14m 29s
Radcliffe & CardioNerds @AHA22: Reduction of Triglycerides With Pemafibrate

Aruna D Pradhan, Gurleen Kaur,

Watch time: 14m 25s
EP 78: Your Guide to Lipoprotein(a) with Dr. Salim S Virani

Salim S Virani, Ankur Kalra,

Listen time: 46:28
FOURIER-OLE: Implications for Real-World Practice

Robert P Giugliano,

Watch time: 2m 56s
FOURIER-OLE: The Trial in Context

Marc S Sabatine,

Watch time: 3m 24s
FOURIER-OLE: Long-term Safety of Evolocumab Therapy in Patients with Evident ASCVD

Michelle O'Donoghue,

Watch time: 3m 30s

Yassir Javaid, , , et al

Watch time: 1h 6m (4 videos)
4 Lipid Late-breaker Highlights from ACC.22 with Dr Erin Michos

Erin D Michos,

Secondary Analysis of CANTOS Finds LDL & HDL Predict Residual Risk of Atherosclerotic Events

Paul M Ridker,

ACC 22: PACMAN-AMI Shows Reduced Plaque Regression in AMI Patients Treated with Alirocumab

Lorenz Räber,

ACC 22: Magnitude & Duration of Effects of a siRNA Targeting Lp(a)

Steven E Nissen,

ACC 22: Results from the TRANSLATE-TIMI 70 Trial

ACC 2022 Late-breaker Discussion: The SuperWIN Trial

Dylan L Steen, Harriette Van Spall,

ACC 2021: Findings From the RESCUE Trial

Paul M Ridker,

ACC 2021 Discussion: The STRENGTH Study

Steven E Nissen, Harriette Van Spall,

AHA 2020: The STRENGTH Trial

AHA 2020: Evinacumab safety and efficacy in HoFH

ACC 2020: Inclisiran Potently and Durably Reduces Ldl-c

AHA 2019: Updates from the EVAPORATE Study

Matthew J Budoff,

Randomized Placebo-Controlled Trial Of Anacetrapib interview with Christopher P. Cannon

Christopher P Cannon,

Articles

Current Evidence and Future Directions of PCSK9 Inhibition

Jiaqian Xu

,

Michael D Shapiro

,

Published:

16 February 2021

Citation:

US Cardiology Review 2021;15:e01.

DOI:

https://doi.org/10.15420/usc.2020.17
  • Views: Views 2875
  • Downloads: Downloads 144

HDL Cholesterol and Adverse Outcomes

Marc P Allard-Ratick

,

Pratik Sandesara

,

Arshed A Quyyumi

,

Laurence S Sperling

,

Published:

12 March 2019

Citation:

US Cardiology Review 2019;13(1):49–53

DOI:

https://doi.org/10.15420/usc.2019.3.2
  • Views: Views 2429
  • Downloads: Downloads 26
  • Citations: 5

Novel Treatments for Cardiovascular Disease

Leo Buckley

,

Ahmed Aldemerdash

,

Citation:

US Cardiology Review 2017;11(2):98–104.

DOI:

https://doi.org/10.15420/usc.2017:20:2
  • Views: Views 1830
  • Downloads: Downloads 8

Dyslipidemia: Current Therapies and Guidelines for Treatment

Edward T Carreras

,

Donna M Polk

,

Citation:

US Cardiology Review 2017;11(1):10–5

DOI:

https://doi.org/10.15420/usc.2016:9:2
  • Views: Views 28327
  • Downloads: Downloads 26
  • Citations: 2